Preoperative Chemotherapy for Operable Breast Cancer Improves Surgical Outcomes in the Community Hospital Setting

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2011 May 12

PMID 21558133

Citations 4

Authors

Ian K Komenaka

Michael L Hibbard

Chiu-Hsieh Hsu

Boo Ghee Low

Jason A Salganick

Marcia E Bouton

Chandra Jha

Affiliations

Soon will be listed here.

Abstract

Background: Preoperative chemotherapy (PC) for operable breast cancer has demonstrated significant benefits in clinical trials. Many patients are treated in the community setting and some may question the applicability of PC outside the university setting. The potential benefits of PC in terms of surgical outcomes in a community practice were examined.

Methods: A retrospective review was performed of stage II and stage IIIA breast cancer patients from January 1, 2002 to July 31, 2009. Surgical outcomes of margin status, volume of lumpectomy, rate of lumpectomy, and re-excision lumpectomy were evaluated.

Results: There were 212 patients included. Seventy-nine percent of patients who underwent PC had a clinical response and 25% had a pathologic complete response. For clinical stage T2 and stage T3 tumors, the PC group underwent lumpectomy more often than patients in the adjuvant chemotherapy (AC) group (78% versus 50%; p = .016 and 60% versus 29%; p = .015, respectively). The rate of close or positive margins in the PC group was half the rate in the AC group (23% versus 46%; p = .04) and this resulted in fewer re-excisions (p = .01). The volume of tissue removed was also smaller in the PC group (143.6 cm³ versus 273.9 cm³; p = .003). Conclusions. PC for operable breast cancer can significantly improve surgical outcomes in community-based practice.

Citing Articles

Neoadjuvant systemic therapy for breast cancer.

Zaborowski A, Wong S Br J Surg. 2023; 110(7):765-772.

PMID: 37104057 PMC: 10683941. DOI: 10.1093/bjs/znad103.

Paradigm shift in the local treatment of breast cancer: mastectomy to breast conservation surgery.

Murugappan K, Saboo A, Kuo L, Ung O Gland Surg. 2019; 7(6):506-519.

PMID: 30687624 PMC: 6323252. DOI: 10.21037/gs.2018.09.01.

Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes.

Volders J, Negenborn V, Spronk P, Krekel N, Schoonmade L, Meijer S Breast Cancer Res Treat. 2017; 168(1):1-12.

PMID: 29214416 PMC: 5847047. DOI: 10.1007/s10549-017-4598-5.

Predictors of margin status after breast-conserving operations in an underscreened population.

Torabi R, Hsu C, Patel P, Dave H, Bouton M, Komenaka I Langenbecks Arch Surg. 2012; 398(3):455-62.

PMID: 23184267 DOI: 10.1007/s00423-012-1023-8.

References

Xing Y, Foy M, Cox D, Kuerer H, Hunt K, Cormier J . Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2005; 93(5):539-46. DOI: 10.1002/bjs.5209. View

Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese R . Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15(7):2483-93. DOI: 10.1200/JCO.1997.15.7.2483. View

Hugh J, Hanson J, Chon U Cheang M, Nielsen T, Perou C, Dumontet C . Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol. 2009; 27(8):1168-76. PMC: 2667821. DOI: 10.1200/JCO.2008.18.1024. View

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View

Badve S . Does tumor size trump biology?. Clin Breast Cancer. 2010; 10(2):111-2. DOI: 10.3816/CBC.2010.n.015. View

Cochrane R, Valasiadou P, Wilson A, Al-Ghazal S, Macmillan R . Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. Br J Surg. 2003; 90(12):1505-9. DOI: 10.1002/bjs.4344. View

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V . A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349(6):546-53. DOI: 10.1056/NEJMoa012782. View

Komenaka I, Torabi R, Nair G, Jayaram L, Hsu C, Bouton M . Intraoperative touch imprint and frozen section analysis of sentinel lymph nodes after neoadjuvant chemotherapy for breast cancer. Ann Surg. 2009; 251(2):319-22. DOI: 10.1097/SLA.0b013e3181ba845c. View

Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M . Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998; 16(1):93-100. DOI: 10.1200/JCO.1998.16.1.93. View

10.

Straver M, Glas A, Hannemann J, Wesseling J, van de Vijver M, Rutgers E . The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2009; 119(3):551-8. DOI: 10.1007/s10549-009-0333-1. View

11.

Wazer D, DiPetrillo T, Schmidt-Ullrich R, Weld L, Smith T, MARCHANT D . Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1992; 10(3):356-63. DOI: 10.1200/JCO.1992.10.3.356. View

12.

Bear H, Anderson S, Brown A, Smith R, Mamounas E, Fisher B . The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21(22):4165-74. DOI: 10.1200/JCO.2003.12.005. View

13.

Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B . Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2002; (30):96-102. DOI: 10.1093/oxfordjournals.jncimonographs.a003469. View

14.

Boughey J, Wagner J, Garrett B, Harker L, Middleton L, Babiera G . Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation. Ann Surg Oncol. 2009; 16(6):1606-11. PMC: 4338983. DOI: 10.1245/s10434-009-0402-z. View

15.

Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I . Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2009; 11(1):55-65. PMC: 3058239. DOI: 10.1016/S1470-2045(09)70314-6. View

16.

Christy C, Thorsteinsson D, Grube B, Black D, Abu-Khalaf M, Chung G . Preoperative chemotherapy decreases the need for re-excision of breast cancers between 2 and 4 cm diameter. Ann Surg Oncol. 2009; 16(3):697-702. DOI: 10.1245/s10434-008-0268-5. View

17.

Vrieling C, Collette L, Fourquet A, Hoogenraad W, Horiot J, Jager J . The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol. 2000; 55(3):219-32. DOI: 10.1016/s0167-8140(00)00210-3. View

18.

Waljee J, Hu E, Newman L, Alderman A . Predictors of re-excision among women undergoing breast-conserving surgery for cancer. Ann Surg Oncol. 2008; 15(5):1297-303. DOI: 10.1245/s10434-007-9777-x. View

19.

Mamounas E, Brown A, Anderson S, Smith R, Julian T, Miller B . Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005; 23(12):2694-702. DOI: 10.1200/JCO.2005.05.188. View

20.

Al-Ghazal S, Fallowfield L, Blamey R . Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity?. Eur J Surg Oncol. 1999; 25(6):571-3. DOI: 10.1053/ejso.1999.0708. View